Study drug AT 1501 for first-time kidney transplant patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 1/2 trial tests how safe AT 1501 is and how it works in people getting their first kidney transplant. It aims to improve transplant outcomes by targeting the immune system, while carefully watching for side effects and immune compatibility issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- This is your first kidney transplant (from a living or deceased donor)
- You can follow birth-control rules during the study and for at least 90 days after your last dose
- You are not using strong whole-body immune medicines other than up to 5 mg prednisone (or equivalent) daily
- You have not used AT 1501 or any similar anti–CD40LG treatment before
- Your donor and your immune testing results must fit specific compatibility rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
This trial is testing a way to help your body accept a kidney transplant without needing lifelong anti-rejection drugs. It is for people getting a kidney from a living donor who is a relative and has a compatible blood type.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
Hear when a new Prevention of Rejection in Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.